Emory University Lung Cancer SPORE

埃默里大学肺癌孢子

基本信息

批准号：
10685410
负责人：
HAIAN FU
金额：
$ 183.99万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-07-10 至 2024-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10685410
关键词：
ABCG2 gene Address Animal Cancer Model Animal Model Area Award Biological Markers Biometry CD8-Positive T-Lymphocytes Cancer Etiology Cancer Patient Cell Fate Control Cessation of life Collaborations Comprehensive Cancer Center Coupled Data Dedications Dependence Deuterium Development Diagnosis Disease Drug resistance Epidermal Growth Factor Receptor Funding Goals Health Sciences Healthcare Systems Hematology Human Immune checkpoint inhibitor Immunologic Factors Immunologist Immunotherapy In Vitro Institution Investigation Ionizing radiation Journals KRAS2 gene Label Location MERTK gene Malignant Neoplasms Malignant neoplasm of lung Mediator Medical Oncology Modernization Molecular Molecular Target Mutate Mutation Neoadjuvant Therapy Non-Small-Cell Lung Carcinoma Oncologist Outcome PD-1 blockade Pathology Patient-Focused Outcomes Patients Phenotype Phosphorylation Phosphorylation Site Play Prognostic Marker Property Publishing Radiation therapy Recommendation Reproduction spores Research Research Personnel Resistance Resource Sharing Role SDZ RAD Safety Scientist Signal Transduction Site T-Lymphocyte TP53 gene Technology Testing Therapeutic Agents Therapy trial Treatment Efficacy Tumor Immunity Universities Work anti-PD1 therapy anti-cancer anticancer research antitumor effect biomedical informatics cancer therapy career clinical application clinical efficacy clinical investigation drug discovery experience improved improved outcome in vivo inhibitor innovation lung cancer cell mTOR inhibition medical schools member molecular targeted therapies mortality multidisciplinary mutant novel novel strategies novel therapeutic intervention patient population phase 1 study preclinical development programmed cell death protein 1 programs radiation resistance resistance mechanism small molecule stem stem-like cell targeted agent targeted treatment therapeutic target therapy resistant translational goal translational scientist tumor tumorigenesis

项目摘要

OVERVIEW SUMMARY/ABSTRACT Lung cancer is the leading cause of cancer-related deaths, with more than 1.6 million deaths/year globally. It is often diagnosed at an advanced stage and is associated with poor outcomes for the majority of patients. This application for a lung cancer SPORE award from Emory University brings together an outstanding and multi- disciplinary team of oncologists, immunologists, drug discovery experts, and translational researchers dedicated to lung cancer research to address critical questions that will improve the outcome for patients with this lethal disease. Our proposed program will have significant impact in two crucial areas of lung cancer management: enhancing the efficacy of immunotherapy and overcoming treatment resistance through the development of novel molecularly targeted agents. Through strong teamwork carried out by this highly collaborative team of dedicated investigators, and building on exciting data published in leading journals by our group since our previous SPORE application, this revised submission aims to achieve substantial improvements in the management of patients with non-small cell lung cancer (NSCLC), through three overall Specific Aims: Aim 1: To evaluate stem-like T cells and improve efficacy of checkpoint inhibitors in NSCLC (Project 1); Aim 2: To target MERTK to improve outcomes for EGFR-mutated NSCLC (Project 2); and Aim 3: To target Bax signaling to overcome treatment resistance in NSCLC (Project 3). The Emory Lung Cancer SPORE program will be supported by close interaction with the Administrative Core (Core 1), Pathology Core (Core 2) and the Biostatistics and Biomedical Informatics Core (Core 3), and will conduct Career Enhancement and Developmental Research Programs (CEP and DRP). The SPORE program will benefit from regular advice and recommendations from External and Internal Advisory Board members regarding its progress and direction. Our program will receive strong institutional support including modern research space, excellent shared resources, and a significant level of matching funds (totaling $2.25M) from the Winship Cancer Institute of Emory University (an NCI-designated Comprehensive Cancer Center), Emory University Woodruff Health Sciences Center, Emory Healthcare System, Emory School of Medicine, and the Department of Hematology and Medical Oncology. Through team-driven innovative research efforts in immunotherapies and molecularly targeted therapeutics, we are confident that this SPORE program, in collaboration with other lung cancer SPORE sites, will have a major positive impact on the management of lung cancer.

概述摘要/摘要肺癌是与癌症相关死亡的主要原因，全球每年超过160万人死亡。这是通常在晚期诊断出，大多数患者的结局差。这埃默里大学（Emory University）申请肺癌孢子奖召集肿瘤学家，免疫学家，药物发现专家和翻译研究人员的纪律团队敬业肺癌研究以解决关键问题，以改善这种致命患者的结果疾病。我们提出的计划将在肺癌管理的两个关键领域产生重大影响：通过发展，增强免疫疗法和克服治疗抗性的功效新型分子靶向剂。通过这个高度协作的团队实施的强大团队合作专门的调查人员，并基于我们小组在领先期刊上发表的令人兴奋的数据以来以前的孢子应用程序，此修订后的提交旨在实现通过三个总体特定目的管理非小细胞肺癌（NSCLC）患者的管理：目标1：评估样干细胞并提高NSCLC检查点抑制剂的功效（项目1）；目标2：靶向MERTK，以改善EGFR突变的NSCLC的结果（项目2）；和目标3：针对Bax 信号传导以克服NSCLC的治疗耐药性（项目3）。埃默里肺癌孢子计划与行政核心（核心1），病理核心（核心2）和生物统计学和生物医学信息学核心（核心3），并将进行职业增强和发展研究计划（CEP和DRP）。孢子计划将从常规建议中受益，外部和内部咨询委员会成员就其进度和方向的建议。我们的计划将获得强大的机构支持，包括现代研究空间，出色的共享资源，以及来自埃默里大学Winship癌症研究所的大量匹配资金（总计225万美元）（NCI指定的综合癌症中心），Emory University Woodruff Health Sciences Center，Emory 医疗保健系统，埃默里医学院以及血液学和医学肿瘤学系。通过团队驱动的免疫疗法和分子靶向疗法的创新研究工作，我们相信该孢子计划与其他肺癌孢子站点合作，将有一个主要对肺癌治疗的积极影响。

项目成果

期刊论文数量（7）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients.

DOI：
10.3390/biomedicines11112916
发表时间：
2023-10-28
期刊：
Biomedicines
影响因子：
4.7
作者：
通讯作者：

Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer.

DOI：
10.3390/cancers13225639
发表时间：
2021-11-11
期刊：
Cancers
影响因子：
5.2
作者：
Yan D;Earp HS;DeRyckere D;Graham DK
通讯作者：
Graham DK

TMPRSS2 and SARS-CoV-2 SPIKE interaction assay for uHTS.

DOI：
10.1093/jmcb/mjad017
发表时间：
2023-08-03
期刊：
Journal of molecular cell biology
影响因子：
5.5
作者：
通讯作者：

Spatially variant immune infiltration scoring in human cancer tissues.

DOI：
10.1038/s41698-022-00305-4
发表时间：
2022-09-01
期刊：
NPJ PRECISION ONCOLOGY
影响因子：
7.9
作者：
Allam, Mayar;Hu, Thomas;Lee, Jeongjin;Aldrich, Jeffrey;Badve, Sunil S.;Gokmen-Polar, Yesim;Bhave, Manali;Ramalingam, Suresh S.;Schneider, Frank;Coskun, Ahmet F.
通讯作者：
Coskun, Ahmet F.

Multiplexed protein profiling reveals spatial subcellular signaling networks.

DOI：
10.1016/j.isci.2022.104980
发表时间：
2022-09-16
期刊：
ISCIENCE
影响因子：
5.8
作者：
Cai, Shuangyi;Hu, Thomas;Venkatesan, Mythreye;Allam, Mayar;Schneider, Frank;Ramalingam, Suresh S.;Sun, Shi-Yong;Coskun, Ahmet F.
通讯作者：
Coskun, Ahmet F.